Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Missed deals, presentation oh my…

<< Previous

Bullboard Posts

Next >>

Post by canadafanon Mar 02, 2024 12:17pm

196 Views

Post# 35911189

Missed deals, presentation oh my…

Like it has been said, ONC do not cancel or back out of PanCan deal. Thst was the PanCan organization canceling ALL future " precicion promise" trials. Due to lack of/ delayed funding from Congress.
A very bad blow to ONCs progress. Not their fault @ all.
The missed presentation? Calgary had a sever westher event. Again, bad timing.

The presentation aside from possibilities, not a major blow.
Moving past thst?

IMHO, the delayed announcement of Q4 update is much more significant.
That is something 100% within Onc control.
We can speculate in any direction on that one.
There is a handful of unanswered questions. Some we may never hear an explanation for.
However Q4 by an6 measure was not good.
The PanCan deal was cancelled. Andrew G & the San Diego office cancelled.
The good news ? PanCan did agree to honour the $5 million grant towards the additional pancreatic cancer trial arm.
With AGM on the horizon, they need to greatly improve the forward looking path.
As I have said too many times. They must announce some form of funding..on a very large scale & soon.
I can nit,nore will I impose my opinions on others. Yes I will certainly offer my opinion. However would never assume others would be of same mindset.
Now, thst I have clarified/ qualified my thoughts......
Id be quite happy to see a buyout N.R. This coming Monday.
Price? $1.5 billion. Or about $18 USD/ ps.
The Canadian exchange would cover my taxes.
I appreciate the comparables the others have posted $5-$10billion sweet spots etc.
Saying that & being realistic. Onc is in a miserable negotiation position right now. Had the PanCan proceeded , they would have a lot more leaversge.
Regardless of what Onc or Onc shareholders want, the company is only worth the discounted value of forward expected income.
" discounted" ... The closer they are to getting Pela to market, the less discount applied to the future value calculations.
We know they are planning in phase 3 , pancreatic cancer trial using Roche Tecentriq. We also know the MBc phase 3 trial " collaboration" says TBD.
Meaning lots of loose ends.